Cancer Family
Pancreaticobiliary Neoplasm
CI-CAN-00000309Explore in graph →
Non-malignant1,205 active trials11 approved drugs92 evidence items
- NCIt
- C223357
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000309Explore in graph →
Clinical trials
5,005 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04931381 | Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer | unknown | Phase 3 | 100 | Changhai HospitalOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT04931394 | Organoid-Guided Adjuvant Chemotherapy for Pancreatic Cancer | unknown | Phase 3 | 200 | Changhai HospitalOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05178628 |
| The Impact of Thromboprophylaxis on Progression Free Survival of Patients With Advanced Pancreatic Cancer(imPaCT-PRO) |
| unknown |
| Phase 3 |
| 450 |
| Michalis KaramouzisOTHER |
| 1 |
| Mar 29, 2022 |
| clinicaltrials |
| NCT03086993 | Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 295 | Delcath Systems Inc.INDUSTRY | 1 | Mar 24, 2022 | clinicaltrials |
| NCT05268692 | Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP | recruiting | Phase 2 / Phase 3 | 500 | Kochi UniversityOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT02591030 | Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours(AMEBICA) | completed | Phase 2 / Phase 3 | 191 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT03472833 | High-dose Vitamin D3 in Pancreas Cancer(VITdCUT) | terminated | Phase 3 | 25 | Medical University of GrazOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT04617821 | AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer | unknown | Phase 3 | 300 | Fudan UniversityOTHER | 1 | Jan 28, 2022 | clinicaltrials |
| NCT04969731 | Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer | recruiting | Phase 3 | 408 | GC Cell CorporationINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT01956812 | Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer(PANCRIT®-1) | terminated | Phase 3 | 334 | Gilead SciencesINDUSTRY | 8 | Aug 16, 2021 | clinicaltrials |
| NCT04961970 | HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC | unknown | Phase 3 | 188 | Shi MingOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT03536182 | Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer(CIPHER) | withdrawn | Phase 3 | 0 | University of Texas Southwestern Medical CenterOTHER | 2 | May 26, 2021 | clinicaltrials |
| NCT04897854 | Timing of Start of systemIc Treatment for Asymptomatic Metastasized Pancreatic Cancer(TIMEPAN) | unknown | Phase 3 | 184 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT04083651 | A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Bausch Health Americas, Inc.INDUSTRY | 1 | May 7, 2021 | clinicaltrials |
| NCT04151719 | An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer | withdrawn | Phase 3 | 0 | Bausch Health Americas, Inc.INDUSTRY | 0 | May 7, 2021 | clinicaltrials |
| NCT03959150 | Metronomic Chemotherapy With Capecitabine for Pancreatic Cancer | unknown | Phase 2 / Phase 3 | 231 | Ruijin HospitalOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT04835064 | Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy. | unknown | Phase 3 | 600 | Fudan UniversityOTHER | 0 | Apr 8, 2021 | clinicaltrials |
| NCT03649035 | Eus-guided Cryothermal Ablation in Stage III Pancreatic Adenocarcinoma | withdrawn | Phase 3 | 0 | Istituto Clinico HumanitasOTHER | 1 | Mar 19, 2021 | clinicaltrials |
| NCT00112658 | Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 / Phase 3 | 342 | UNICANCEROTHER | 1 | Mar 8, 2021 | clinicaltrials |
| NCT03766295 | Masitinib Plus Gemcitabine in Pancreatic Cancer | completed | Phase 3 | 377 | AB ScienceINDUSTRY | 8 | Dec 8, 2020 | clinicaltrials |
| NCT04183478 | The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer | unknown | Phase 2 / Phase 3 | 600 | RenJi HospitalOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT02340728 | Endoscopic Biliary Co-axial Stent Placement Plus/Minus Use of Radiofrequency Ablation (RFA) for Clearance of Occluded Self Expandable Metal Stents (SEMS) in Patients With Distal Biliary Obstruction From Unresectable Biliary-pancreatic Malignancies | completed | Phase 3 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02923921 | Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer(Sequoia) | completed | Phase 3 | 567 | Eli Lilly and CompanyINDUSTRY | 13 | Oct 19, 2020 | clinicaltrials |
| NCT02172976 | Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma | completed | Phase 2 / Phase 3 | 40 | Krankenhaus NordwestOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT04167007 | FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX(GEMFOX) | unknown | Phase 3 | 400 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 18, 2020 | clinicaltrials |
| NCT03579758 | Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer | withdrawn | Phase 3 | 0 | Emory UniversityOTHER | 1 | Jun 5, 2020 | clinicaltrials |
| NCT01072981 | Immunotherapy Study for Surgically Resected Pancreatic Cancer | completed | Phase 3 | 722 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT01836432 | Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer(PILLAR) | terminated | Phase 3 | 302 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT02043288 | Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer | completed | Phase 3 | 310 | Orient Europharma Co., Ltd.INDUSTRY | 7 | Apr 15, 2020 | clinicaltrials |
| NCT00026338 | Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer | completed | Phase 3 | 569 | NCIC Clinical Trials GroupNETWORK | 19 | Apr 2, 2020 | clinicaltrials |
| NCT01438476 | Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas | completed | Phase 3 | 178 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 12, 2020 | clinicaltrials |
| NCT01926236 | Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers(ABC06) | completed | Phase 3 | 162 | The Christie NHS Foundation TrustOTHER | 1 | Jan 28, 2020 | clinicaltrials |
| NCT03771846 | HAIC Versus Systemic Chemotherapy for Unresectable ICC | unknown | Phase 3 | 188 | Shi MingOTHER | 1 | Dec 5, 2019 | clinicaltrials |
| NCT00844649 | Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas | completed | Phase 3 | 861 | CelgeneINDUSTRY | 11 | Nov 25, 2019 | clinicaltrials |
| NCT03610100 | Acelarin First Line Randomised Pancreatic Study(ACELARATE) | suspended | Phase 2 / Phase 3 | 328 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 1 | Oct 29, 2019 | clinicaltrials |
| NCT02082522 | Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS) | terminated | Phase 3 | 28 | Concordia Laboratories Inc.INDUSTRY | 5 | Aug 28, 2019 | clinicaltrials |
| NCT02108145 | Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 70 | Air Force Military Medical University, ChinaOTHER | 1 | Aug 1, 2019 | clinicaltrials |
| NCT01314027 | Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer | terminated | Phase 3 | 38 | University of ZurichOTHER | 4 | Jul 25, 2019 | clinicaltrials |
| NCT02404363 | Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy(PANCREADOGREL) | terminated | Phase 3 | 39 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 25, 2019 | clinicaltrials |
| NCT01470443 | Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma | unknown | Phase 3 | 240 | Samsung Medical CenterOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT00030732 | Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 3 | 319 | Swiss Cancer InstituteOTHER | 4 | May 15, 2019 | clinicaltrials |
| NCT02117479 | Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) | terminated | Phase 3 | 321 | Incyte CorporationINDUSTRY | 12 | Mar 26, 2019 | clinicaltrials |
| NCT02356640 | EUS-guided CGN for Inoperable Cancer | terminated | Phase 2 / Phase 3 | 3 | Chinese University of Hong KongOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT03239184 | Bioinformation Therapy for Pancreatic Cancer | completed | Phase 2 / Phase 3 | 120 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jan 25, 2019 | clinicaltrials |
| NCT03779035 | Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection(AdBTC-1) | unknown | Phase 3 | 460 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT00789633 | Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer | completed | Phase 3 | 353 | AB ScienceINDUSTRY | 5 | Dec 17, 2018 | clinicaltrials |
| NCT03398291 | Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy | unknown | Phase 3 | 300 | Fudan UniversityOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT01900327 | Neoadjuvant Treatment in Resectable Pancreatic Cancer(NEOPA) | terminated | Phase 3 | 32 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT01458717 | Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer | completed | Phase 2 / Phase 3 | 58 | Seoul National University HospitalOTHER | 1 | May 2, 2018 | clinicaltrials |
| NCT02284139 | Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects | completed | Phase 2 / Phase 3 | 90 | Dong-A University HospitalOTHER | 1 | Apr 23, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Aug 2, 2022source: clinicaltrials